The digital healthcare market in the U.S. was worth approximately $90 billion in 2022. The share of personalised medicine is rapidly growing. As a result, the demand for drug therapy safety with great potential for evidence based PGx testing is increasing.
EIT Health’s Bridgehead program is aimed at European healthcare companies looking to expand their business beyond their home market. The program enables scale-ups to connect with world-leading incubators and accelerators having the expertise and resources to support the market transition.
HMG Systems Engineering’s participation in Bridgehead aims to successfully introduce PGXperts to the North American market. For this we want to evaluate the market between September 2022 and July 2023 and prepare the regulatory path to FDA approval. We want to win two renowned hospitals for the validation of the product.
